Law firm Bleichmar Fonti & Auld LLP announced on October 27, 2026 that a securities fraud class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain senior executives, alleging misrepresentations about demand for its Opteon refrigerant products.

Key Highlights

  • Case caption: The action is captioned Darcy v. The Chemours Company, No. 26-cv-1299, pending in the U.S. District Court for the District of Delaware.
  • Lead plaintiff deadline: Investors have until December 7, 2026 to ask the court to be appointed to lead the case.
  • Stock drop: Chemours's stock fell $3.34 per share, or 18.63%, from $17.93 per share on August 4, 2026 to $14.59 per share on August 5, 2026, according to the filing.
  • Alleged guidance cut: On August 4, 2026, Chemours reportedly cut its 2026 adjusted EBITDA guidance by approximately 11%, to $775M-$825M from the prior range of $800M-$900M.
  • Core allegation: The complaint asserts Chemours failed to disclose that customers were already oversupplied with Opteon products, resulting in an "oversupplied channel heading into 2026."
  • Legal claims: The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Chemours Opteon Oversupply Allegations and the August 2026 Stock Decline

According to the announcement by Bleichmar Fonti & Auld LLP, the class action centers on Chemours's statements about demand for its Opteon products, a line of refrigeration chemicals with a reduced ozone-depletion footprint. The complaint alleges that Chemours represented "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the U.S. AIM Act, legislation enacted in late 2020 that directed the EPA to oversee a transition to alternative refrigerants. Chemours also provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M-$900M, driven by "higher . . . demand" in its Opteon segment, according to the filing.

The complaint alleges that Chemours failed to disclose that customers were already oversupplied with Opteon products as a result of the AIM Act transition, creating an "oversupplied channel heading into 2026." On August 4, 2026, when Chemours announced its Q2 2026 financial results, the company disclosed an approximately 1% year-over-year decrease in net sales and reduced its 2026 adjusted EBITDA guidance by about 11%. The company also disclosed that customers had "built additional inventory" of Opteon products the prior year and that aftermarket channels had been filled.

Following this disclosure, Chemours's stock dropped 18.63% on August 5, 2026, according to the filing. The law firm states that all representation in the matter is on a contingency fee basis, with shareholders not responsible for court costs or litigation expenses, subject to court approval of any fees and expenses.

What Was Disclosed

Bleichmar Fonti & Auld LLP announced a securities fraud class action against NYSE:CC and certain senior executives, alleging misrepresentations about Opteon demand. The lead plaintiff deadline is December 7, 2026, and the case is pending in the U.S. District Court for the District of Delaware.